CD274 and non-small cell lung carcinoma: In this context, there have been several efforts to develop OMICS- and imaging-based predictive biomarkers that could be used in addition or as a surrogate to PD-L1 staining to better identify the subgroup of patients most likely to benefit from these ICIs, thereby increasing progression-free survival (PFS) and overall survival (OS) of NSCLC patients3–5.